How GSK, Chiesi Farmaceutici, Regeneron/Sanofi, Novartis, and AB Science are trying to benefit patients afflicted with Inadequately Controlled Asthma?
Delveinsight
AUGUST 13, 2020
GlaxoSmithKline’s Trelegy Ellipta for the treatment of Inadequately Controlled Asthma. GlaxoSmithKline is worth mentioning here, as it is presenting key posters and studies on Trelegy Ellipta in uncontrolled asthma patients. GSK is developing this therapy in collaboration with Innoviva, Inc.,
40 
Let's personalize your content